Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting safety, tolerability, and pharmacokinetics/pharmacodynamics of ACZ885 (canakinumab) in patients with Type 2 Diabetes Mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• ACZ885 (canakinumab)

Snippet

Sponsor: Novartis | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2012-02-13